Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.

@article{Ueno2013RandomizedPI,
  title={Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.},
  author={Hideki Ueno and Tatsuya Ioka and Masafumi Ikeda and Shinichi Ohkawa and Hiroaki Yanagimoto and Narikazu Boku and Akira Fukutomi and Kazuya Sugimori and Hideo Baba and Kenji Yamao and Tomotaka Shimamura and Masayuki Sho and Masayuki Kitano and Ann-lii Cheng and Kazuhiro Mizumoto and J Z S Chen and Junji Furuse and Akihiro Funakoshi and Takashi Hatori and Taketo Yamaguchi and Shinichi Egawa and Atsushi Sato and Yasuo Ohashi and Takuji Okusaka and Masao Tanaka},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 13},
  pages={1640-8}
}
PURPOSE The present phase III study was designed to investigate the noninferiority of S-1 alone and superiority of gemcitabine plus S-1 compared with gemcitabine alone with respect to overall survival. PATIENTS AND METHODS The participants were chemotherapy-naive patients with locally advanced or metastatic pancreatic cancer. Patients were randomly assigned to receive only gemcitabine (1,000 mg/m(2) on days 1, 8, and 15 of a 28-day cycle), only S-1 (80, 100, or 120 mg/d according to body… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
147 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 147 extracted citations

Similar Papers

Loading similar papers…